Home » Clinical Trials » Medical Areas
Therapeutic Areas: Psychiatry/Psychology | Pediatrics/Neonatology
Disease Category: Obsessive-Compulsive Disorders
Trial Information
Maximizing Treatment Outcome in OCD
New York State Psychiatric Institute, New York City
This study compares the effectiveness of two proven treatment strategies for OCD patients who are currently on a serotonin reuptake inhibitor (SRI, i.e., clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, or escitalopram) but still have residual symptoms. Participants remain on their current medication and receive either cognitive-behavioral therapy (CBT) consisting of exposure and ritual prevention or an additional medication (risperidone). The goal is to compare these two augmentation strategies, each of which has been found effective in prior studies. All treatment is at no charge. Note: Patients who do not improve after 8.5 weeks of treatment will be offered at no-cost the treatment they did not initially receive (either the CBT or the add-on medication).
PatientInclusionCriteria
- 18-70 years
- Genders: both
Key Inclusion Criteria:
- Primary diagnosis of OCD
- Currently on a stable and adequate dose of an SRI
Patient Exclusion Criteria:
- Medical or psychiatric conditions that would make participation in the study unsafe
- Patients who have already had an adequate trial of these augmentation strategies while on a serotonin reuptake inhibitor
New York State Psychiatric Institute
New York State Psychiatric Institute
1051 Riverside Drive #69
New York NY 10032
Phone: 212-543-5367
View Google Map
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
